SCHEMBL14770655

SCHEMBL14770655

CCOc1ccc2[nH]c(C(C)c3ccc(OC)c(Br)c3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HTT P42858 2/20 0.46
HIF1A Q16665 1/20 0.38
HPGD P15428 4/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
HSD17B10 Q99714 2/20 0.34
ESR2 Q92731 1/20 0.34
NPC1 O15118 2/20 0.34
LMNA P02545 2/20 0.34
RAB9A P51151 2/20 0.34
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770652 0.90 MEN1 (0.37) MEN1KMT2AHTTALDH1A1MAPT
SCHEMBL14770719 0.88 MEN1 (0.48) MEN1KMT2AHTTHIF1AHPGD
SCHEMBL14770535 0.85 MEN1 (0.53) MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL14770503 0.82 AMY1A (0.42) MAPTTP53TSHRHPSE
SCHEMBL14770650 0.81 AMY1A (0.50) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL14770545 0.79 CACNA1C (0.44) MEN1KMT2AHTTHIF1AHPGD
SCHEMBL12065638 0.78 MEN1 (0.40) MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL14770601 0.78 PTGES (0.51) MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL14770716 0.78 MLKL (0.41) MEN1KMT2AHTTALDH1A1MAPT
SCHEMBL14770561 0.78 MEN1 (0.50) MEN1KMT2AHTTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MEN1 2676/4885KMT2A 4545/4885HTT 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.